Similar articles for PMID: 29462515

Year	Number of Results
1805	1
1806	1
1816	1
1947	1
1948	1
1999	1
2000	5
2001	2
2002	1
2003	2
2004	5
2005	1
2006	4
2007	2
2008	5
2009	2
2010	1
2011	6
2012	10
2013	6
2014	17
2015	11
2016	15
2017	11
2018	15
2019	23
2020	8
2021	14
2022	9
2023	7
2024	1

1

Risk Factor for Diabetes Mellitus and High Blood Glucose With HMG-CoA Reductase Inhibitors Using a Postmarketing Surveillance Database in Japan.

Hashiguchi M, Maruyama J, Shimizu M, Takahashi D, Shiga T. Hashiguchi M, et al. Clin Pharmacol Drug Dev. 2018 Nov;7(8):800-810. doi: 10.1002/cpdd.444. Epub 2018 Feb 20. Clin Pharmacol Drug Dev. 2018. PMID: 29462515

2

Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan .

Hashiguchi M, Hakamata J, Shimizu M, Maruyama J, Shiga T, Mochizuki M. Hashiguchi M, et al. Int J Clin Pharmacol Ther. 2018 Jul;56(7):310-320. doi: 10.5414/CP203237. Int J Clin Pharmacol Ther. 2018. PMID: 29701171

3

Statin-associated incident diabetes: a literature review.

Park ZH, Juska A, Dyakov D, Patel RV. Park ZH, et al. Consult Pharm. 2014;29(5):317-34. doi: 10.4140/TCP.n.2014.317. Consult Pharm. 2014. PMID: 24849689 Review.

4

Statin safety: an assessment using an administrative claims database.

Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, Davidson MH. Cziraky MJ, et al. Am J Cardiol. 2006 Apr 17;97(8A):61C-68C. doi: 10.1016/j.amjcard.2005.12.011. Epub 2006 Jan 30. Am J Cardiol. 2006. PMID: 16581331

5

Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening.

Ooba N, Setoguchi S, Sato T, Kubota K. Ooba N, et al. BMJ Open. 2017 Jun 30;7(6):e015935. doi: 10.1136/bmjopen-2017-015935. BMJ Open. 2017. PMID: 28667223 Free PMC article.

6

Statin treatment and new-onset diabetes: a review of proposed mechanisms.

Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Brault M, et al. Metabolism. 2014 Jun;63(6):735-45. doi: 10.1016/j.metabol.2014.02.014. Epub 2014 Feb 25. Metabolism. 2014. PMID: 24641882 Review.

7

Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.

Mantel-Teeuwisse AK, Klungel OH, Egberts TC, Verschuren WM, Porsius AJ, de Boer A. Mantel-Teeuwisse AK, et al. Drug Saf. 2004;27(1):63-70. doi: 10.2165/00002018-200427010-00004. Drug Saf. 2004. PMID: 14720086

8

Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase^®.

Montastruc F, Benevent J, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Montastruc F, et al. Fundam Clin Pharmacol. 2019 Feb;33(1):108-112. doi: 10.1111/fcp.12406. Epub 2018 Aug 30. Fundam Clin Pharmacol. 2019. PMID: 30098074

9

Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.

Cho Y, Choe E, Lee YH, Seo JW, Choi Y, Yun Y, Wang HJ, Ahn CW, Cha BS, Lee HC, Kang ES. Cho Y, et al. Metabolism. 2015 Apr;64(4):482-8. doi: 10.1016/j.metabol.2014.09.008. Epub 2014 Sep 28. Metabolism. 2015. PMID: 25312577

10

HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients.

Choe EY, Wang HJ, Kwon O, Cho Y, Huh KH, Kim MS, Kim YS, Ahn CW, Cha BS, Lee HC, Kang ES. Choe EY, et al. Transplantation. 2014 Feb 27;97(4):419-25. doi: 10.1097/01.TP.0000437427.04733.ad. Transplantation. 2014. PMID: 24285338

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

172 results

Results by year